Research Priorities and Eligibility

Immunoglobulins

In order to advance science and improve patient care with CSL Behring's products in the area of immunoglobulin research, we support, with provision of drug and/or total or partial funding, high-quality research that is initiated, designed, implemented, and sponsored by external investigators and is involved with the immunoglobulin products Privigen® and/or Hizentra®. Support is provided based on the scientific merit of the proposal as well as alignment with the following specific areas of interest:

Primary Immunodeficiency (PID)

Proposals that increase the knowledge of the efficacy and safety of the immunoglobulins in PID indications, specifically route of administration, subclinical infections in diagnosed PID patients with respiratory tract engagement, quality of life, wear-off, manual push, flexible dosing/patient preference, and undiagnosed PID

Secondary Immune Deficiency (SID)

Proposals that increase the knowledge of immunoglobulins in regard to efficacy and safety, specifically the combination of immunoglobulins with products that cause drug-induced SID in conditions such as multiple myeloma and chronic lymphocytic leukemia (CLL)

Peripheral Neuropathy

Proposals that increase the knowledge of efficacy and safety of the immunoglobulins, specifically pharmacokinetics in chronic inflammatory demyelinating polyneuropathy (CIDP), including wear-off, dose titration, dose conversion from intravenous immunoglobulins (IVIg) to subcutaneous immunoglobulins (SCIg), loading dose and dosing by body mass index (BMI) or fat percent versus weight, quality of life in CIDP patients, health economics in CIDP and specific sub-populations such as elderly and pediatric patients

Hizentra and Privigen are manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and Privigen® are registered trademarks of CSL Behring AG.

Coagulation

To advance science and improve patient care with CSL Behring's products, we support through total or partial funding external investigators who initiate, design and implement high-quality research that is focused on our new recombinant products, IDELVION® and AFSTYLA®. Support is provided based on the scientific merit of the proposal as well as alignment with the following specific areas of interest:

Hemophilia A and B

Real-world experience with CSL Behring's new recombinant coagulation products for hemophilia A and B, including

  • Transition to the new products
  • Health outcome studies, including factor consumption, quality of life data, adherence
  • Personalized prophylaxis
  • Joint health/target joints, including biomarkers of disease progression
  • Use in special populations

Hemophilia A only

  • Role of von Willebrand Factor (VWF) in reducing inhibitor development
  • Use of assays and pharmacokinetic (PK) data in guiding AFSTYLA® dosing
  • Immune tolerance induction with AFSTYLA®

AFSTYLA and IDELVION are manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
AFSTYLA® and IDELVION® are registered trademarks of CSL Behring Recombinant Facility AG.

Specialty Products

In order to advance science and improve patient care with CSL Behring's products in the areas of oral anticoagulant-associated bleeding, acquired bleeding disorders, and hereditary angioedema we support through the provision of drug and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Support is provided based on the scientific merit of the proposal as well as alignment with the following specific areas of interest:

Oral Anticoagulant-Associated Bleeding
  • Clinical studies and experience with Prothrombin Complex Concentrates (PCCs) for the management of acute major bleeding in patients treated with Vitamin K antagonists (VKAs) or novel oral anticoagulants (NOACs)
  • Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or NOACs
Acquired Bleeding
  • Clinical studies of PCCs as a hemostatic agent in perioperative bleeding and trauma-induced coagulopathy
  • Basic science research with PCCs in trauma-induced coagulopathy
Hereditary Angioedema (HAE)
  • Health Outcome studies on C1 Esterase Inhibitor (C1-INH) including quality of life and adherence
  • Clinical studies and experience with novel treatment strategies to replace C1-INH
  • Use of C1-INH in special patient populations (eg pregnancy, pediatrics)
Our Request Requirements have recently changed. Please take a moment to review them.